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Mast cells are critical effectors of allergic disease that can be activated by numerous 
stimuli. We have examined mast cell control by the inflammatory cytokine, IL-33, as well as 
IgG. In the first study reported here, we found that the synthetic glucocorticoid, dexamethasone, 
   
potently and rapidly suppressed IL-33-induced cytokine production from murine bone marrow–
derived and peritoneal mast cells, as well as human mast cells. Dexamethasone also antagonized 
IL-33-mediated enhancement of IgE-induced cytokine production and migration. Although 
dexamethasone had no effect on IL-33-induced phosphorylation of MAP kinases or NFκB p65 
subunit, it antagonized AP-1- and NFκB-mediated transcriptional activity. Finally, 
intraperitoneal administration of dexamethasone completely abrogated IL-33-mediated 
peritoneal neutrophil recruitment and prevented plasma IL-6 elevation. These data demonstrate 
that steroid therapy may be an effective means of antagonizing the effects of IL-33 on mast cells 
in vitro and in vivo, acting partly by suppressing IL-33-induced NFκB and AP-1 activity. In the 
second study reported here, we found that Fcγ receptor cross-linkage activated the transcription 
factor Stat5B through a Fyn kinase-dependent pathway. We then showed that STAT5B is critical 
for IgG-induced cytokine production by mast cells but not macrophages. To expand these 
studies, we employed the K/BxN model of inflammatory arthritis, which has roles for mast cells 
and macrophages. In this model, Fyn or STAT5B deficiency only affected the arthritic flare that 
primarily depends on mast cell degranulation, without affecting the severity of the joint swelling. 
By contrast, Lyn kinase deficiency significantly exacerbated arthritis. These studies indicate a 
clinically relevant, lineage-restricted role for the Lyn/Fyn-STAT5 cascade. Collectively, our 
work demonstrates that mast cell activation by diverse stimuli can be suppressed by steroid 
intervention and selectively targeted by disrupting kinase-transcription factor pathways.
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Chapter I: General Introduction 
Mast cells are innate immune cells, which arise from pluripotent hematopoietic stem cells 
(HSC) of the bone marrow along the myeloid pathway. The most striking morphological feature 
of mast cells is their cytoplasm filled with of electron rich secretory granules. This formed the 
basis of their discovery in 1878, when German histologist Paul Ehrlich observed some ‘well fed’ 
cells in human connective tissues after staining with aniline dyes. The cell was named as 
Mastzellen because he thought the granules provide nourishment and ‘Mast’ denotes food or 
feeding in the German language (1, 2). 
Mast cell progenitors (MCps) egress the bone marrow and circulate in the blood. These 
precursors can be identified by their expression of the high affinity receptor for IgE, FcεRI and 
the receptor for stem-cell-factor (SCF), c-Kit. They exit into tissues by trans-endothelial 
migration at a pace which makes them virtually undetectable in the blood. Once in the tissues, 
MCps develop into mature mast cells of two major subclasses, connective tissue mast cells 
(CTMC) and mucosal mast cells (MMC), which exhibit phenotypical differences such as distinct 
protease expression profiles. Collectively, mature mast cells are present throughout the body, 
particularly in association with structures such as blood vessels and nerves and are abundant at 
the host-environment interfaces, like skin and mucosal surfaces. Their anatomical location 
allows them to serve as sentinels of immune activation (1, 2).  
Mast cells can be activated through a variety of stimuli, antigen-IgE-mediated 
aggregation of FcεRI being the most commonly studied. Certain toxins, lipopolysaccharides, the 
endogenous alarmin IL-33, and antigen-IgG complexes are also mast cell activators. Mast cell 
activation generally happens in three distinct phases. Within minutes after activation the 
preformed mediators stored in the cytoplasmic granules are released, followed by de novo 
  
  
 
2 
synthesis and secretion of lipid mediators like leukotriene C4, prostaglandin D2, and platelet 
activating factor. Hours later, newly-synthesized cytokine and chemokines, including IL-6, IL-4, 
IL-13, TNF, IL-10, MCP-1 (CCL2), MIP-1 (CCL3)(1) are secreted. However, mast cell 
activation does not necessarily involve all three phases. For example, activation by 
lipopolysaccharides or IL-33 results in cytokine/chemokine production without degranulation (2, 
3). 
The most frequently studied and clinically relevant mast cell activator is antigen-
mediated crosslinking of mast cell-associated IgE, leading to aggregation of FcεRI. This receptor 
is a tetramer made up of an IgE binding α chain, a signal-amplifying β chain, and a dimer of 
signal transducing γ chains. Downstream of FcεRI receptor aggregation, the Lyn kinase-Syk-
LAT pathway and Fyn kinase-Gab2-PI3K pathways are two chief signaling pathways (4).   
Granule constituents can be divided into various categories including lysosomal enzymes 
such as β-hexosaminidase, biogenic amines like histamine and serotonin, mast cell-specific 
proteases like tryptases, chymases, and carboxy peptidase-3 (CPA-3), non-mast cell-specific 
proteases like MMP-9 and granzyme B, cytokine and growth factors such as TNF and VEGF, 
and proteoglycans such as chondroitin sulfate, heparin, and serglycin (1). Among these, the most 
clinically important component is arguably histamine. It has multiple effects, including 
activating afferent nerve cells, stimulating smooth muscle contraction leading to 
bronchoconstriction, and inducing vascular permeability and systemic vasodilation. Mast cell-
specific proteases, especially chymase mMCP-4 and CPA-3, are unique for their capacity to 
degrade an endogenous toxin endothelin-1, generated during sepsis, and various toxins present in 
venoms of snakes and honeybees(5, 6). These proteases could also contribute to inflammatory 
responses by activating protease active receptor-2 (PAR-2) on fibroblast; proteolytic activation 
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of matrix metalloproteinase pro-enzymes (pro-MMPs); and by degrading collagen and other 
extracellular matrix components (1).   
Similar to monocytes/macrophages, mast cells are long-lived cells which can re-enter the 
cell cycle and proliferate once stimulated. Mast cell survival, proliferation and phenotypic 
characteristics can be influenced by systemic and local factors in the tissues. Among the factors 
that affect mast cell numbers and phenotype, the chief ones are SCF, IL-3, and Th2-associated 
cytokines such as IL-4 and IL-9 (3). 
Collectively, mast cells can exhibit extensive phenotypic plasticity that is altered by 
many factors acting through autocrine, paracrine and/or systemic mechanisms.  
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Chapter II: Materials and Methods 
Reagents  
Recombinant mouse IL-3, stem cell factor, mature, cleaved human and mouse IL-33, Low 
Endotoxin Azide-Free (LEAF)-purified anti-CD16/32 antibody (Clone 93), Rat anti-mouse IgG 
(clone Poly4054), FITC-conjugated anti-mouse CD11b (clone M1/70) (101206), PE-conjugated 
anti-mouse Gr-1 (108408), APC-conjugated anti-mouse TNF (506308), APC-conjugated anti-
mouse IL-6 (504508), APC-conjugated anti-CD107a, PE-conjugated anti-CD63, F4/80-
conjugated BV421 (clone BM8), APC-conjugated CD45 (clone 30-F11) were purchased from 
BioLegend (San Diego, CA, USA). FITC-conjugated anti-mouse T1/ST2 (101001F) was 
purchased from MD Biosciences (St. Paul, MN, USA). Anti-mouse CD16/32 Fc block (clone 
2.4G2), and puriﬁed mouse IgE (clone C38-2, k isotype), Alexafluor 647-conjugated anti-
phospho-Stat5 (clone 47), PE-conjugated Ly6G (clone I-A8) antibodies were purchased from BD 
Biosciences (San Diego, CA, USA). DNP-HSA was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Dexamethasone and RU-486 were purchased from Tocris Bioscience (Bristol, UK). 
All Western blot antibodies were purchased from Cell Signaling Technology (Danvers, MA, 
USA). Phospho-p38 MAPK (T180/Y182) (D3F9) rabbit 4511, p38 MAPK rabbit (9212), 
phospho-p44/42 MAPK (T202/Y204) rabbit (9101), p-44/42 MAPK (Erk1/2) (L34F12) mouse 
(4696), phosphoNFkB p65 (Ser536) (93H1) rabbit (3033), NFkB p65 (L8F6) mouse (6956), 
phospho-SAPK/JNK (T183/Y185) rabbit (9251), and SAPK/JNK rabbit (9252) were used as 
primary antibodies. Anti-rabbit IgG (H+L) (DyLight 800 4X PEG Conjugate) (5151) and anti-
mouse IgG (H+L) (DyLight 680 4X PEG conjugate) (5470) were used as secondary antibodies. 
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Luciferase reporter assay reagents were purchased from Promega (Madison, WI, USA). Total 
Stat5A antibody (sc-1081) was purchased from Santa Cruz Biotecgnologies.  
Animals 
C57BL/6J, 129/SvJ, NOD/shiLtJ, 129/Sv-Lyntm1sor/J, B6.126S7-Fyntm1Sor/J, C.129-Stat5btm1Hwd/J, 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). KRN Transgenic 
mice were imported from Christophe Benoist, Harvard University. NOD/shiLtJ were crossed 
with KRN transgenic mice to obtain K/BxN mice. All the experiments were performed with 
approval from the Virginia Commonwealth University Institutional Animal Care and Use 
Committee.  
K/BxN model of arthritis 
Arthritis was induced by i.p. administration of pooled sera obtained from arthritic K/BxN mice 
on days 0 and 2 and were scored as described (7). In brief, each paw was given a score of 0 (no 
inflammation), 1 (swelling restricted locally), 2 (swelling sufficient to make ankle and mid-foot 
approximately equal in thickness to fore-foot) and 3 (Reversal of normal V shape if the foot) at 
indicated time points. Paw and wrist thickness was measured using a spring-loaded caliper as 
described (8). Mice sacrificed 15 or 40 minutes post injection were used to collect plasma by 
cardiac puncture. Joints were washed with equal volume of PBS to collect exudates.  Histamine 
level in the plasma and joint exudates was quantified by ELISA. Mice sacrificed at indicated 
days post-injection were used to collect joint exudates. After ACK lysis, these exudates were 
stained for analysis by flow cytometer to quantify innate immune cells infiltrated to the joints. 
IgG-mediated PSA 
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Mice were injected i.v. with 500 µg of rat anti-mouse CD16/CD32 (clone 2.4G2). The core body 
temperature was measured using a rectal probe (Braintree scientific) at indicated time points. 
Mice were then sacrificed and plasma collected by cardiac puncture was analyzed by ELISA for 
cytokines. 
Mouse mast cell culture 
Mouse bone marrow-derived mast cells (BMMC) were cultured as published (9). In brief, single 
suspensions were prepared by flushing the bone marrow from murine femurs. The pellets 
obtained after ACK lysis were suspended in complete RPMI + IL-3 and SCF and were expanded 
for 21-28 days. At this point ~95% cells are cKit+/ FcЄRI+, verified by flow cytometric analysis. 
Cells obtained through a peritoneal lavage, were processed and cultured similarly for 10 days 
before utilization.  
Human mast cell cultures 
Protocols for human tissues were approved by the human studies Institutional Review Board at 
the University of South Carolina. Surgical skin samples obtained from the Cooperative Human 
Tissue Network of the National Cancer Institute were used to isolate skin mast cells which were 
cultured as described elsewhere (10). In brief, skin was separated from subcutaneous fat and 
minced into small pieces. They were subjected to a number of digestion steps using human skin 
digestion buffer to obtain single cell suspension. Cells were cultured in X-VIVO medium and 
recombinant human SCF for 4 weeks before use. MC purity was determined to be 100% pure by 
toluidine blue staining. 
IgE-mediated activation 
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Human MCs and mouse BMMCs were sensitized overnight with DNP-speciﬁc mouse IgE (1.0 
mg/ml for human MC; 0.5 mg/ml for BMMCs). Unbound IgE was washed out followed by re-
suspending cells at 1*106 cells/ml concentration in complete medium containing growth factors. 
Cells were stimulated for 6 hours (murine BMMC) or 16 hours (human cells) with DNP-HSA 
(50µg/ml) before analyzing mediator release in the supernatant.  
IgG-mediated activation 
Immune complexes were made by incubating 50 µg/ml of Clone 93 and Clone Poly4054 in 
complete medium for at-least half an hour at 37°C. Murine BMMC cell pellets were re-
suspended in these pre-formed complexes at 1*106 cells/ml concentration with growth factors for 
6 hours before collecting supernatants.  
Macrophage culture and activation 
Cells isolated from bone marrow were expanded in complete medium with MCSF (30 ng/ml) for 
6 days in tissue culture treated flasks from CELLSTAR. Non-adherent cells were excluded 
during each feeding cycle. On day 7, adherent cells were isolated by trypsin treatment and either 
stained for surface markers and analyzed by flow cytometer or re-plated at a concentration of 
1*106 cells/ml in tissue culture-treated plates from CELLSTAR. Once the re-plated cells became 
adherent, the media was replaced with media containing pre-formed immune complexes made as 
described above, to activate cells. Supernatants collected at 6 hours after activation were 
analyzed by ELISA. 
Cytokine assessment by ELISA 
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ELISA kits purchased from Peprotech (Rocky Hill, NJ, USA) or BioLegend were used. ELISAs 
were performed with culture supernatants according to the manufacturer’s protocols. ELISAs for 
human cytokines were developed using BD OptEIA reagents from BD Biosciences (Franklin 
Lakes, NJ,). 
mRNA analysis 
BMMCs were activated with IL-33 for 2 h. Cells were harvested, and total RNA was extracted 
with TRIzol reagent (Thermo Fisher Scientiﬁc, Grand Island, NY, USA). RNA was quantiﬁed 
with the NanoDrop 1000 UV–vis spectrophotometer (Thermo Fisher Scientiﬁc, Waltham, MA, 
USA), according to the manufacturer’s recommended protocol. For cytokine mRNA detection, 
cDNA was synthesized by using qScript cDNA Synthesis from Quanta Biosciences 
(Gaithersburg, MD, USA). The CFX96 Touch Real-Time PCR Detection System (Bio-Rad, 
Hercules, CA, USA) was used to amplify message with PerfeCTa SYBR Green SuperMix 
(Quanta Biosciences). Primers for IL-6 (forward: 59-TCCAGTTGCCTTCTTGGGAC-39, 
reverse: 59-TCCAGTTGCCTTCTTGGGAC-39), TNF (forward: 59-
AGCACAGAAAGCATCATCCGC-39, reverse: 59-TGCCACAAGCAGGAATGAGAAG-39), 
b-actin (forward: 59-GATGAC GATATCGCTGCGC-39, reverse: 59-
CTCGTCACCCACATAGGAGTC-39), were purchased from Euroﬁns MWG Operon 
(Huntsville, AL, USA). Ampliﬁcation conditions for qPCR consisted of a heat-activation step at 
95°C for 2 min followed by 40 cycles of 95°C for 15 s, 55°C for 30 s, and 60°C for 1 min. All 
melting curve analyses were performed between 50°C and 95°C. Results were normalized to 
housekeeping genes by using the relative Livak Method. 
Western blot analysis 
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Western blot analysis was performed using 25 µg total cellular protein, as described previously 
(9).  Odyssey CLx infrared imaging system (LiCor, Lincoln, NE, USA) was utilized to visualize 
and quantify blots. 
Luciferase assay 
3*106 BMMCs were transfected per condition with 1.2 mg of pGL4.74[hRluc/ TK] vector 
encoding luciferase gene from Renilla reniformis under the HSV-TK promoter and 6 mg of 
either pGL4.44[luc2p/AP1 RE/Hygro] or pGL4.32 [luc2p/NFkB RE/Hygro] vector encoding the 
luciferase gene from Photinus pyralis (ﬁreﬂy) under the AP-1 and NFκB response elements, 
respectively. All transfections were performed using Amaxa Nucleofector (Lonza; Allendale, NJ, 
USA) with program T-5 in 20% FBS and 50 mM HEPES (pH 7.5) (11). Cells were used 48 h 
after transfection. Luciferase activity among the lysates was measured with a Dual-Luciferase 
Reporter Assay System, by the GloMax 20/20 luminometer, program DLR-2-INJ (Promega). 
Flow cytometry 
For surface staining, cells washed in PBS after the appropriate treatment were incubated in Fc 
block and staining or isotype control antibodies for 30 min at 4°C, washed with PBS and re-
suspended in FACS buffer (PBS, 3% FBS, and 0.1% sodium azide), and analyzed by ﬂow 
cytometry on a FACSCalibur (BD Biosciences). 
Intra-cellular staining for cytokines 
BMMC activated with IL-33 (50 ng/ml) ± Dex (1 µM) for 90 min were treated with 5 µM 
monensin for 5 h, ﬁxed 20 min in 4% paraformaldehyde, washed twice in PBS and stored 
overnight at 4°C. Cells were then pelleted and re-suspended in saponin buffer (PBS, 0.1% BSA, 
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0.01M HEPES, and 0.5% saponin) for 20 min at room temperature. After two washes, cell 
pellets were incubated in Fc block and staining or isotype control antibodies for 30 min at 4°C. 
Analyzing phospho-proteins by flow cytometry 
Cells were activated for indicated times. Activation was halted and cells were fixed with 1.6% 
paraformaldehyde for 10 minutes followed by methanol treatment to permeabilize them. Cells 
treated in this fashion were stained with appropriate anti-phospho-protein antibody and analyzed 
by flow cytometer.  
Migration assay 
IgE-sensitized BMMCs were washed, re-suspended at 2*106 cells/ml in migration medium 
[cRPMI, with FBS is replaced by 10 mg/ml BSA) + IL-3 (1 ng/ml)] ± Dex (1 µM) or vehicle, an 
hour before use. Polycarbonate (8 mm) 24-well Transwell inserts (Corning, Corning NY, USA) 
were coated in migration medium for 1 h at 37°C before use. Migration wells contained 900 µl 
migration medium ±antigen (50 ng/ml) ±IL-33 (50 ng/ml) ±Dex (1 mM) or vehicle. Coated 
inserts were placed in the migration wells, and 200 µl of the re-suspended cells was placed in the 
top chamber. Cells were incubated for 16 h at 37°C, after which cells from quadruplicate aliquots 
from the migration well were counted via ﬂow cytometry with propidium-iodide exclusion 
staining. 
Neutrophil recruitment assay 
Age- and gender-matched groups of C57BL/6 mice (10–16 week old) received intraperitoneal 
injections of Dex (2 mg/kg) or vehicle and 1 mg recombinant IL-33 in 200 µl of sterile PBS. 
After four hours, mice were sacrificed by CO2 asphyxiation, followed by peritoneal lavage to 
isolate cells. Cells were analyzed for surface expression of CD11b and GR-1 using flow 
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cytometry. Cardiac punctures were performed to collect plasma, which was used to analyze 
cytokines by ELISA. 
Statistical analysis   
Data shown in each ﬁgure of chapter IV are the SEM of the indicated number of samples, unless 
otherwise speciﬁed. P-values were calculated by paired or unpaired Student’s t test unless 
mentioned otherwise. P ≤ 0.05 indicated statistical signiﬁcance (Prism software; GraphPad, San 
Diego, CA, USA). 	
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Chapter III. Part 1. Abstract 
The Src family kinases Lyn and Fyn provide critical and opposing controls over mast cell 
responses to IgE and IgG. Fyn activates, while Lyn impedes IgE-mediated STAT5 
phosphorylation, which is required for IgE-mediated cytokine production. However, the role of 
STAT5B in IgG-mediated activation is unknown. Therefore, we examined the importance of 
STAT5 in IgG signaling, and broadened these studies to test the role for Lyn, Fyn, and Stat5 in 
IgG-mediated inflammation in vivo. Consistent with IgE, STAT5B KO mast cells produced 
significantly less cytokines and chemokines after IgG-induced activation in vitro. On the other 
hand, IgG-induced cytokine production in STAT5B KO macrophages was unaffected, indicating 
that the non-redundant role of STAT5B might be lineage-restricted. To expand these studies, we 
employed the K/BxN model of inflammatory arthritis, which has roles for mast cells and 
macrophages. In this model, Fyn or STAT5B deficiency only affected the arthritic flare that 
primarily depends on mast cell degranulation, without affecting the severity of the joint welling. 
By contrast, Lyn deficiency significantly exacerbated arthritis. These studies indicate a clinically 
relevant, lineage-restricted role for the Lyn/Fyn-STAT5 cascade, showing that inhibitory effects 
of Lyn kinase are critical in macrophage-driven inflammatory diseases. 
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Chapter III. Part 2. Introduction 
III. 2. 1. Fcγ receptors 
 There are four classes of murine Fcγ receptors identified to date: FcγRI, FcγRIIB, 
FcγRIII and FcγRIV. Of these, FcγRI, FcγRIII and FcγRIV are activating receptors; all of the 
activating receptors share the γ chain that is responsible for signaling, with FcεRI, the high 
affinity receptor for IgE.  FcγRIIB consists of an ITIM (immunoreceptor tyrosine-based 
inhibitory motif) in the cytoplasmic domain, which allows it to act as an inhibitory receptor (12).  
 Fcγ receptors are widely expressed throughout that hematopoietic system. Among innate 
immune cells, macrophages express all the activating and inhibitory receptors (FcγRI-IV), 
neutrophils express the inhibitory FcγRIIB and inflammatory FcγRIII and FcγRIV. Mast cells 
possess FcγRIII and FcγRIIB. While dendritic cells express FcγRI, FcγRIIB and FcγRIII, NK 
cells solely express activating FcγRIII (13).  
Four different subclasses of IgG antibodies are found in mice, IgG1, IgG2a, IgG2b and 
IgG3 (13). 
FcγRI is the only high affinity receptor. It exclusively binds IgG2a with the affinity of 
108 or 109 M-1. All other receptors possess 100-1000 fold lower affinity in low to medium 
micromolar range. They also show a wider IgG-subclass specificity. While the medium affinity 
(KA: 2-3*107 M-1) receptor FcγRIV binds to IgG2a and IgG2b, the low affinity receptors FcγRIII 
and IIB bind to IgG1, IgG2a and IgG2b. IgG3 interacts very weekly with all Fcγ receptors. The 
low affinity of Fcγ receptors prevents binding of monomeric IgG molecules that are always 
present at high levels in the serum and hence protects from non-specific activation of pro-
inflammatory responses. On the other hand, the high affinity FcγRI is constantly occupied by its 
ligand. Cell activation initiates only after receptors are crosslinked by an antigen (14, 15). 
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Overall, this family of Fcγ receptors is an example of how simultaneous stimulation of signaling 
downstream of activating and inhibitory receptors sets a threshold for activation resulting in 
well-balanced immune response. Pro-inflammatory responses ensue when the positive signals 
dominate resulting in pathogenic clearance. Disturbance in the threshold leads to either weak 
responses that are insufficient to clear an infection or lead to loss of tolerance and induction of 
autoimmunity (15). 
Orthologous proteins corresponding to these Fcγ receptors have been found in other 
mammalian species. FcγR systems in human and primates are the most diverse. In brief, humans 
possess FcγRI, RIIA, RIIC, RIIIA and RIIIB as activating receptors and FcγRIIB as an inhibitory 
receptor and four subclasses of IgG antibodies, IgG1-IgG4 (16).    
Although results obtained using a murine model provide a valuable tool to decipher the 
role of Fcγ receptors, differences in the cytoplasmic domains, cellular expression patterns, 
specificities and affinities for IgG subclasses need to be considered when extrapolating data 
obtained from a murine system to humans. 
III. 2.2. Systemic anaphylaxis 
Anaphylaxis is a rapid onset, acute, life threatening systemic hypersensitivity reaction 
triggered by an antigen like venoms, food, medicines, therapeutic antibodies. It is characterized 
by vascular permeability, vascular leak, hypotension, drop in core body temperature (130).  
In 1902, Portier and Richet first introduced the term anaphylaxis. It happened during their 
attempts to induce improved resistance to a toxin using dogs as their experimental animals. 
Following repeated administration of sublethal doses of the toxin, dogs were re-exposed to small 
amounts of the same toxin a few weeks later. Unexpectedly, some of the dogs died within 
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minutes of re-exposure. The immunizations that were supposed to offer protection or 
prophylactic effects did the opposite. Hence this increased sensitivity was referred to as 
anaphylaxis, from the Greek word ana, meaning backward, and phylaxis, meaning protection. 
Richet did extensive pioneering work in this field and was awarded the Nobel Prize in medicine 
and physiology in 1913 (130, 131). 
Around 1990, several studies had recognized the contribution of IgE-mast cell pathway to 
systemic anaphylaxis (130, 131). In 1994, Leder and colleagues induced active systemic 
anaphylaxis in mice deficient for IgE. These mutant mice, which were capable of producing 
other immunoglobulin isotypes normally, underwent anaphylaxis similar to wild type mice. 
Although complement activation was found to be dispensable for this type of anaphylactic 
reaction, it did depend on the existence of a functional immune system, as shown by 
investigations using immune-deficient RAG-2 and SCID mice (132).  This was a pivotal study 
acknowledging the existence of non-IgE pathways for hypersensitivity reactions.  
Subsequently, it was realized that sensitization of mice for active anaphylaxis induces 
generation of IgE and IgG1 antibodies, specific for the antigen. Anaphylaxis can be successfully 
induced passively by administration of IgG1 antibodies, a reaction predominantly mediated 
through FcγRIII. The alpha chain of FcεRI and mast cells both are not essential for active 
anaphylaxis and IgG1 mediated passive anaphylaxis but presence of mast cells does enhance the 
intensity of the reaction in both cases (131). While this new pathway is now recognized as the 
‘alternate pathway’ of anaphylaxis, IgE/FcεRI/mast cell, basophil mediated one is considered as 
the ‘classical pathway’ (17).   
As mentioned before, the classical pathway involves activation mast cells and basophils 
through FcεRI. Antigen-induced crosslinking of IgE associated with FcεRI on these cells results 
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in rapid degranulation leading to release of proteases and histamine that is primarily responsible 
for development of shock, detected as hypothermia. Platelet-activating factor (PAF) also plays a 
role (17, 18). On the other hand, an alternate pathway is primarily mediated by IgG1 and 
proceeds through FcγRIII (19, 20). Studies identify macrophages as the predominant effectors of 
anaphylaxis through the alternate pathway (18). PAF, rather than histamine, is primarily 
responsible for hypothermia in this system (21, 22). While IgG1 also binds the inhibitory 
receptor FcγRIIb, the inhibitory effects on macrophages are outweighed by stimulatory effects, 
probably due to higher expression of FcγRIII (131, 133, 134).  FcγRIII is also expressed on all 
myeloid cells including mast cells, basophils and neutrophils. The contribution of basophils and 
neutrophils to IgG-mediated anaphylaxis has been debated. Active systemic anaphylaxis (ASA) 
models using antigen plus an adjuvant have pointed out that use of different adjuvants might be 
the root of these discrepancies, as adjuvant choice during sensitization might have affected 
production of a particular IgG isotype (23-25) (135). A passive systemic anaphylaxis (PSA) 
model that utilizes IgG2-immune complexes to induce hypothermia has shown that the 
contribution of neutrophils activated through FcγRIV matters significantly (135). Finally, a 
recent study of ASA in an adjuvant-free murine model showed that anaphylaxis in their system 
proceeds through both classical and alternate pathways, with histamine and PAF contributing to 
hypothermia. While mast cells and macrophages both are essential, neutrophils are dispensable 
(24). 
Although the clinical features of these two independent pathways resemble one another, 
induction of hypothermia through the alternative pathway requires higher antibody 
concentrations and 100-fold more antigen than those required by the classical pathway. Small 
quantities of antigen needed to trigger the classical pathway may not make this pathway a more 
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frequent one, as the responses are dramatically altered when antigen-specific IgG and IgE both 
are present. IgG antibodies being present in serum can prevent IgE-mediated anaphylaxis, by 
intercepting antigen before it binds to mast cell-associated IgE. As a result, IgG antibodies block 
anaphylaxis when the antigen concentration is low and mediate anaphylaxis induced by large 
quantities of antigen. For a similar reason, large quantities of antigen trigger anaphylaxis mainly 
through alternate pathway, even in the presence of antigen specific-IgE. Under such a situation 
anaphylaxis through both the pathways will be triggered only when the amount of antigen 
exceeds the capacity of IgG antibody to interfere with its binding to mast cell associated IgE 
(26). This is why bridging the gaps in our knowledge regarding factors that alter anaphylaxis 
through alternate pathway is critical. 
In our studies we used the monoclonal antibody 2.4G2 to induce passive anaphylaxis 
through the alternate pathway. This antibody has specificity for the activating receptor FcγRIII 
and inhibitory receptor FcγRIIb, mimicking binding of IgG1-immune complexes (136).  
 
III. 2.3. K/BxN serum transfer model of inflammatory arthritis 
 The first report on the K/BxN arthritis model came out in 1996 from the Mathis/Benoist 
lab. This model was discovered by crossing TCR transgenic KRN mice on the C57BL/6 
background with NOD mice. The F1 generation, denoted as K/BxN, spontaneously developed 
severe arthritis by 4-5 weeks of age (27). The KRN mice possess a TCR that recognizes bovine 
ribonuclease reductase peptide (RNases 43-56) presented by I-Ak MHC class II molecule on 
C57BL/6 background. When crossed with NOD mice K/BxN TCR recognizes a self-peptide 
bound to NOD derived I-Ag7 MHC class II molecule on antigen presenting cells. This peptide is 
a ubiquitously expressed self-antigen, glucose-6-phosphate isomerase (G6PI) (28). Activated T 
cells subsequently interact with B cells through TCR: I-Ag7 –MHC class II molecules and CD-
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40:CD40L engagement and promote a polyclonal B-cell activation that results in production of 
disease-inducing immunoglobulins (IgGs). It was subsequently realized that administration of 
purified IgGs or serum from K/BxN mice to wild type mice leads to a transient but robust 
arthritis that wanes in 15 days but can be made persistent by repeated administrations of the sera 
(29). Since transfer of K/BxN sera leads to reproducible disease in many strains of mice, this 
became a model to study effector mechanisms in progression of the disease.  
 Autoimmune inflammatory attack against the ubiquitously expressed G6PI occurs in the 
distal joints. Studies have shown that G6PI is present on the articular surfaces in distal joints in 
healthy mice and is amplified in arthritic mice (30). Anti-G6PI IgGs localize specifically to the 
distal joints within minutes after injection and form immune complexes on the cartilage surface. 
Subsequent studies also revealed that soluble G6PI-anti-G6PI immune complexes form in the 
serum. These soluble complexes are believed to facilitate access for antibodies to distal joints by 
binding to FcγRIII receptors, possibly on neutrophils in the blood. It has been suggested that this 
leads to secretion of vasoactive mediators locally leading to increase in vascular permeability, 
allowing the soluble immune complexes to enter perivascular tissue in the joint, causing local 
mast cell activation through FcγRIII crosslinking (31, 32).  
  The connection between the immune complexes and cell activation is Fcγ receptors. The 
crucial role of Fcγ receptors in disease development in this system is shown by studies using 
FcγR KO mice, some of which exhibit protection from arthritis development. While absence of 
FcγRI did not affect disease intensity (33), FcγRIII KO mice show delayed onset and reduced 
severity (33-35). FcγRIV expressed by monocytes/macrophages and neutrophils holds a critical 
role in disease pathology (36).  FcγRIV is also important for activation of osteoclasts, and hence 
is responsible for bone destruction during this disease (37). As expected, the inhibitory Fc 
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receptor FcγRIIb has an immunosuppressive role (34, 35, 38).   In summary, K/BxN serum 
transfer-induced arthritis is mediated predominantly through the activating receptor FcγRIII; 
FcγRIV contributes, and FcγRIIb has an inhibitory role.  
 The dominant isotype among the anti-G6PI auto-antibodies is IgG1(30). This isotype is a 
weak activator C1q, a component of classical complement pathway. Hence, unlike other arthritis 
models, the alternate pathway of complement activation plays a critical role in induction of the 
disease in the K/BxN model in addition to IgG1-immune complex mediated activation of 
FcγRIII (33).   
 Neutrophils play a pivotal role in the K/BxN serum transfer arthritis model. Their 
importance has been established through studies using anti-Ly6G monoclonal antibody (39) and 
Gfi knockout mice (7). Macrophages are important effector cells in this model. While lack of 
macrophages by a depleting antibody results in a complete protection from disease, 
reconstitution with peritoneal macrophages induces arthritis (40).  
 The role of mast cells in the K/BxN model is controversial. Initial studies with mast cell 
knockout strains KitW/Wv and Kitlsl/sl-d showed little or no clinical signs of the disease, and mast 
cell reconstitution in these strains led to disease induction (41). Subsequently, the importance of 
mast cells in the initial phase of arthritis through release of IL-1 was highlighted (42). Studies 
have also shown that mast cells release tryptase/heparin complexes that induce neutrophil 
chemoattractants in cultured fibroblast like synoviocytes, and mice lacking mast cell-specific 
proteases mMCP-6 or mMCP-7 exhibited impaired arthritis (43). It has now been realized that 
the lack of disease in KitW/Wv strain cannot be attributed solely to mast cells, as this strain has 
defects in other cell lineages including neutrophils. Another mast cell deficient strain, KitW-sh, 
exhibited full susceptibility (44), further questioning the necessity of mast cells for arthritis 
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development in this model. However, the KitW-sh strain has more neutrophils than wild type 
animals, suggesting that the results obtained could not be attributed to any single lineage of cells. 
Finally, a recent mast cell deficient strain Cpa3cre/+ that does not lack any other cell lineage 
developed K/BxN arthritis normally (45)suggesting that mast cells might contribute, but are 
dispensable in this model.  
Only a few studies until now report the existence of a transient joint swelling (flare) that 
could be observed approximately 30 minutes post-injection in the K/BxN model (8, 46). 
Interestingly, this flare is significantly lower in mast cell-deficient KitW-sh mice that otherwise 
show full disease susceptibility. This indicates mast cell are non-redundant for the immune-
complex mediated vascular leak that happens minutes after administration of the arthritic sera.  
 Although the K/BxN serum transfer arthritis (STA) model serves as a valuable tool for 
understanding effector mechanisms in antibody-driven arthritis, it is essential to know the 
similarities and differences between this model and human rheumatoid arthritis (RA). 
Similarities exist in terms of leukocyte invasion, pannus formation, synovitis, cartilage and bone 
destruction, and remodeling of the joint. While STA develops within a few days, RA progression 
is a long process happening over several years. Inflammation during the K/BxN STA model is 
solely based on auto-antibodies. However, in RA many different mechanisms are involved along 
with auto-antibodies. Moreover, RA patients generally possess antibodies of several different 
specificities. Rheumatoid factor that is often found among RA patients is absent in this model 
(47). 
 
III.2.4. Stat5 
Signal transducers and activators of transcription (STAT) family proteins are 
evolutionary conserved transcription factors that are typically activated downstream of type I/II 
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cytokine receptors due to ligand-mediated dimerization of the receptor chains. Stats are typically 
found in the cytoplasm under quiescent, homeostatic conditions and translocate to the nucleus 
after activation-induced dimerization through the classical JAK-Stat5 pathway (48, 49). 
Stat5 is unique among this family as two genes present on two different chromosomes, 
Stat5a and Stat5b, encode it.  While Stat5a encodes for a 91kDa protein made of 793 amino acids, 
Stat5b encodes for a 90kDa protein consisting of 786 amino acids. Shown below is a cartoon for 
the structure of Stat5A and B molecules from Grimley et al (50). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A high degree of structural homology between these fraternal twins might be the result of 
a relatively recent evolutionary divergence. Stat5A and Stat5B share more than 90% homology 
in their amino acid sequence. At the C-terminus (shown at the top) is the trans-activation domain 
(TA). Stat5A and B differ by 20 amino acids in the TA domain (shown in green). Followed by 
that is the Src homology (SH2) domain that encompasses the positionally-conserved tyrosine 
residue (shown in red). They differ in only 6 amino acids in their DNA-binding domain and 18 
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amino acids in their N-termini (N)(shown towards the bottom). The target binding site for both 
Stat5A and B is TTCC(A>T)GGAA (49). 
 Studies from our laboratory have shown that Stat5 is activated downstream of stem cell 
factor (SCF) in bone marrow derived mast cells (137) and that expression of Stat5 is crucial for 
mast cell development and proliferation (51). Our lab also showed that Stat5 is activated 
downstream by FcεRI and that the absence of Stat5 abrogates mediator release from mast cells 
(52). In contrast to the classical pathway of Stat5 activation, FcεRI-induced Stat5 activation is 
independent of Jak2, and instead require Fyn kinase (53).  
 
III. 2.5. Role of Fyn and Lyn in mast cell signaling 
  The Src family kinase Lyn is a 53-56 kDa protein (138) that holds an apical position in 
signaling downstream of FcεRI in mast cells. Although Lyn tyrosine kinase initiates signaling 
through the Syk-LAT pathway, it is a well-documented dual regulator of mast cell signaling. Lyn 
Deficiency leads to increased IgE-mediated degranulation and mediator release from mast cells 
and exacerbated anaphylaxis (54). These responses are partly driven by hyper activation of Fyn 
kinase in the absence of Lyn and also through loss of recruitment of inhibitory proteins, 
including CSK-binding protein, SHIP-1, SHP-2, and DOK-1 which decrease signaling through 
MAPKinase and PI3Kinase pathways (4).  
 On the other hand, Fyn kinase, a 59 kDa Src family protein tyrosine kinase, is a well-
documented positive regulator of mast cell signaling downstream of FcεRI. Phosphorylated Fyn 
binds to the adaptor protein Gab2, initiating the PI3Kinase cascade. This enhances calcium flux 
and transcription factor activity, ultimately inducing degranulation and cytokine release (139, 
140, 141).  
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III.2.6. Background 
 As mentioned, activating Fcγ receptors share the signaling γ chain with FcεRI. A 
previous report from our lab has shown that Lyn and Fyn retain their roles as negative and 
positive regulators of signaling, respectively, downstream of Fcγ receptors in mast cells, 
macrophages and basophils in vitro. However, in vivo, Lyn but not Fyn controls the severity of 
IgG-induced passive systemic anaphylaxis (55).  
 Another report from our lab showed that Stat5 is phosphorylated downstream of FcεRI 
crosslinking in mast cells, and that the absence of Stat5 abrogates release of early mediators like 
histamine and leukotrienes as well cytokines (52). A close look at the mechanism by which Stat5 
is activated downstream of IgE crosslinking uncovered the crucial role of Fyn kinase in 
phosphorylation of Stat5 and also suggested that Lyn kinase affects phosphorylation of Stat5 in a 
negative fashion (53). Subsequently studies using siRNA knockdown revealed that Stat5B has a 
critical role in cytokine secretion, while Stat5A is dispensable.  
 The current study focuses on the activation and function of Stat5B downstream of Fcγ 
receptor activation in mast cells. This study also explores the relationship between Fyn kinase 
and Stat5 activation post-FcγR activation and the role of the Lyn/Fyn-Stat5 cascade in IgG-
mediated diseases in vivo. 
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Chapter III. Part 3: Results 
Previous studies in our lab have shown that in mast cells, antigen-mediated crosslinking 
of IgE leads to transient tyrosine phosphorylation of the transcription factor Stat5, leading to its 
activation (52). This is a direct result of signaling downstream of FcεRI. A follow up study 
revealed that IgE-mediated Stat5 activation proceeds through the Fyn kinase pathway (53). As 
Fcγ receptors on mast cells share the gamma subunit with FcεRI, they exhibit similar signaling 
cascades (55). Hence we tested if activation of Fcγ receptors on mast cells, through IgG immune 
complexes (IgG XL), leads to a similar effect. As per our hypothesis, we found that Stat5 is 
tyrosine phosphorylated downstream of IgG XL in mast cells, and that this is significantly 
reduced in the absence of Fyn kinase (Figure III.1.A). 
Downstream of IgE crosslinking, Stat5 activation is known to be functionally important, 
as its deficiency causes a significant defect in mast cell mediator release and cytokine production 
(52). Between the two highly similar but functionally different isoforms of Stat5 (142), Stat5B 
was found to be selectively important for IgE-mediated mast cell cytokine release (55). Hence 
we decided to explore the functional importance of Stat5 in IgG signaling using Stat5B KO 
BMMC. In agreement with our hypothesis, Stat5B KO BMMC exhibited significant defects in 
cytokine and chemokine production following IgG XL (Figure III.1.B). On the other hand, mast 
cell degranulation quantified using anti-LAMP-1 antibody, was mildly affected (Figure III.1.C).  
As we used BMMC for all in vitro experiments, it was necessary to ensure that the in 
vitro development kinetics were similar between wild type and Stat5B KO mast cells. We 
cultured and analyzed mast cells at multiple time points during their in vitro expansion and 
differentiation as described in (56). Stat5B KO mast cells did not exhibit significant differences 
in their development kinetics (Figure III.2).  
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Next, we decided to test the functional significance of Stat5B in IgG-mediated 
inflammation in vivo. For that, first we chose PSA as a model. Systemic shock similar to that 
induced by IgE-FcεRI-mast cell pathway can also be induced through an alternative pathway 
mediated by IgG antibodies that bind to the activating low-affinity receptor FcγRIII on mast cells 
and macrophages (17). We modeled this by injecting a monoclonal antibody 2.4G2 i.v. to induce 
anaphylaxis. Hypothermia measured by drop in the core body temperature was used as a measure 
of the severity of the reaction. Interestingly, we noticed no significant difference in the extent of 
hypothermia between wild type and Stat5B KO mice (Figure III.3.A). The primary mediators of 
hypothermia during anaphylaxis are vasoactive agents such as histamine and PAF (18). These 
are released from cells minutes after activation. As we saw that in vitro degranulation responses 
among Stat5B KO mast cells were not significantly different than those among wild type mast 
cells, in vivo histamine release might not be significantly different either, resulting in comparable 
hypothermia.  
We also compared plasma cytokine levels between wild type and Stat5B KO mice 
undergoing anaphylaxis as a measure of systemic inflammation and the late phase response. To 
our surprise, plasma MIP-1 levels were also not significantly different (Figure III.3. B). TNF 
levels were undetectable. 
Although mast cells contribute to IgG-mediated passive systemic anaphylaxis, it is 
predominantly mediated through FcγRIII-mediated macrophage activation. The contrast between 
the in vitro and in vivo data prompted study of Stat5B function in macrophage mediator release. 
Hence, we isolated primary macrophages from bone marrow of wild type and Stat5B KO mice, 
and cultured them in cRPMI + MCSF as described in the Methods section. We found no 
difference in the yield of mature macrophages among wild type and Stat5B KO strains (Figure 
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III.4.A, B). Next, we analyzed IgG XL-induced release of TNF and MIP-1 from these mature 
macrophages and found that the absence of Stat5B does not alter mediator release from 
macrophages (Figure III. 4A, C). These data indicate that importance of Stat5B in FcγR-
mediated function can vary with cell lineage, being critical in mast cells but dispensable among 
macrophages.  
The paralogs Stat5A and Stat5B are believed to have overlapping as well as specific 
targets (50). Hence, we determined if Stat5 as a whole is necessary for IgG XL-induced cytokine 
production in macrophages. For this, we chose the FDA-approved anti-psychotic drug, Pimozide 
(57). Pimozide selectively decreases Stat5 phosphorylation without reducing Jak kinase or MAP 
Kinase function. The concentrations at which Pimozide inhibits Stat5 activation, has minimal 
effects on phosphorylation of Stat1, Stat3 and Src family kinases. It has been shown to 
specifically down-regulate Stat5-induced transcription without affecting that of Stat1 and NFκB 
(58), and has been proven effective in mouse models of AML, in which pathogenesis depends on 
constitutive Stat5 activation (57).  In our experiments, Pimozide reduced IgG XL-induced TNF 
and MIP-1α production from macrophages in a dose-dependent manner (Figure III.4.D) 
indicating that Stat5 may have a role in IgG-mediated macrophage function. Further studies 
using siRNA to deplete Stat5A versus Stat5A and Stat5B are underway to elucidate this potential 
function and the importance of each paralog. 
The necessity of Stat5B for mast cell mediator release, its dispensability for mediator 
release from macrophages and the requirement of active Stat5 for the same downstream of Fcγ 
receptors raised a possibility that macrophages might compensate for the loss of Stat5B by up-
regulating Stat5A expression. To explore this hypothesis, we compared Stat5A protein levels 
between wild type and Stat5B KO cells for both the lineages. We saw no significant difference in 
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the levels of total Stat5A between wild type and Stat5B KO mast cells or macrophages (Figure 
III.5. A, B), indicating that compensation by Stat5A enhancement is not occurring. The 
mechanism behind the lineage-specific role of Stat5B downstream of IgG XL needs further 
exploring.  
Then we decided to utilize the K/BxN serum transfer arthritis model as a second means 
of testing the in vivo significance of Stat5B in IgG-FcγR signaling. Similar to IgG-induced PSA 
(Figure III.3), the absence of Stat5B did not offer any protection from the disease, reflected by 
comparable clinical indices, increase in wrist and ankle thickness, and the total number as well as 
percentage of neutrophils infiltrating the arthritic joints of wild type and Stat5B KO mice (Figure 
III. 6).   
In addition to the delayed joint inflammation, recent studies have thrown light on the 
arthritic flare that is observed at 30-40 minutes after administration of arthritic sera in this model 
(46). This immediate swelling is believed to be the result of activating local mast cells by the 
accumulating immune complexes. Proteases released by degranulating mast cells near the joint 
play a critical role in inducing vasodilation and vascular permeability (8), resulting in a transient 
joint swelling. We analyzed the flare in wild type and Stat5B KO mice post-injection. 15 minutes 
after administration of the sera, joint exudates from wild type mice had significantly more 
histamine than those from Stat5B KO mice (Figure III.7A),  but it was undetectable in the 
plasma from both the strains at this time point (data not shown). Joint swelling became 
detectable around 30 minutes post injection. Both strains exhibited very mild ankle swelling.  
Wrist swelling on the other hand, was significantly greater in wild type mice and negligible in 
Stat5B KO. Clinical index, which allows overall assessment of inflammation without limiting the 
evaluation to a particular axis in the joint, also showed a significant difference between wild type 
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and Stat5B KO mice, indicating an overall lower inflammation among the knockouts (Figure 
III.7.B). At 40 minutes post injection histamine levels in the joint-exudates and in the plasma of 
wild type mice were significantly more than those of Stat5B KO mice. Non-arthritic control mice 
had undetectable or less than 100 ng/ml histamine (data not shown) (Figure III.7.C). In summary, 
these data indicate that the absence of Stat5B abrogates mast cell responses in vivo.  
 Studies have shown that Fyn kinase acts as a positive mediator of IgG signaling and its 
absence affects IgG XL-induced release of early and late mediators from mast cells. Unlike our 
observations with Stat5B, the role of Fyn kinase is not lineage restricted. Fyn KO macrophages 
also exhibit abrogated IgG-induced mediator release in vitro (55). Hence, we were curious to 
know the effects of Fyn deficiency on the development of K/BxN serum transfer arthritis. To our 
surprise, Fyn KO mice developed arthritis of similar severity as wild type mice (Figure III.8.B, 
C). Interestingly, mast cell mediated arthritic flare was milder among Fyn KO mice compared to 
the wild type mice (Figure III.8.A). This data mirrors a previous study published from our lab 
that showed that Fyn KO mice were not protected from 2.4G2 PSA but serum histamine levels 
were significantly low in the absence of Fyn during IgG-induced anaphylaxis (55). 
Lyn kinase is a negative regulator of IgG-mediated mast cell signaling. Like Fyn, the 
negative regulatory role of Lyn kinase is conserved among macrophages. Its absence exacerbates 
IgG-induced PSA in vivo (55). We performed K/BxN STA model on Lyn KO mice. Disease 
severity measured by clinical index, change in wrist and ankle thickness was significantly more 
in Lyn KO mice compared to the wild type mice (Figure III.9.A-B). Analysis of cells infiltrated 
to the joints also showed significantly greater fraction of myeloid cells in Lyn KO mice 
compared to the wild type mice. This indicates that absence of Lyn kinase exacerbates IgG-
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mediated inflammation in vivo. Studies to assess the severity of the arthritic flare among the Lyn 
KO mice are currently ongoing.   
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Chapter III. Part 4: Discussion 
The current study focuses on IgG crosslinking-induced mediator release from mast cells 
and macrophages, and the role of the Lyn/Fyn-Stat5 cascade in IgG-mediated inflammatory 
diseases. As previous studies from our lab have indicated that Stat5B selectively plays a role in 
IgE-induced mediator release (53), we began our investigation using Stat5B KO mast cells.  
In our system, wild type and Stat5B KO BMMC activated with IgG XL showed reduced 
cytokine secretion but no significant difference in degranulation (Figure III.1). The fact that 
absence of a transcription factor does not interfere with the release of pre-formed mediators but 
does abrogate release of cytokines, a process requiring de novo transcription, is logical. However, 
BMMC do not exhibit a robust degranulation downstream of IgG XL. We analyzed 
degranulation by quantifying surface levels of LAMP-1/CD107a, which is a well-accepted 
marker for degranulation (59). Total MFI of the population and gMFI among CD107a-positive 
cells did show a significant increase compared to unactivated cells, but only 5% cells became 
positive for CD107a after activation. This percentage is much lower than what we routinely 
observe downstream of IgE-mediated activation (around 40-70%; data not shown). We also tried 
to analyze degranulation by measuring histamine levels in mast cell supernatants after IgG XL 
and found no significant increase in histamine release (data not shown). Hence, the IgG-induced 
degranulation response is quite weak in vitro.  
In contrast to this, histamine levels in the joint exudates and in plasma of arthritic mice 
were significantly different between the two mouse strains (Figure III.7. B, C). As mast cell 
degranulation is the predominant source of released histamine, it is possible that the absence of 
Stat5B does reduce mast cell degranulation in vivo. Previous studies in our lab using Stat5 A/B 
KO BMMC showed that Stat5 is critical for IgE-mediated histamine and leukotriene B4 (LTB4) 
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production (52). Taking all of this into consideration, we cannot rule out the possibility of Stat5B 
playing a role in early responses, and need to further test the role of Stat5A. Further, in vitro and 
in vivo mast cell responses could vary for several reasons. BMMC are less mature in terms of 
intracellular granule architecture than in vivo differentiated mast cells (1). Studies also indicate 
that peritoneal mast cells express higher surface levels of FcγRIII and hence exhibit better 
activation responses downstream of IgG XL (60). Hence, we plan to assess IgG-induced 
peritoneal mast cell degranulation responses and also to measure histamine levels.   
 Interestingly, 15 minutes post-injection of the arthritic sera, joint exudates had detectable 
amounts of histamine (Figure III.7.A), while this was still undetectable in plasma (data not 
shown). By comparison, 40 minutes after injection, amounts of histamine in exudates increased 
compared to the earlier time point and it was detectable in plasma (Figure III.7.C). These data fit 
the mechanism of initiation of K/BxN arthritis (47) and highlight the role played by local mast 
cells in vascular permeability and vasodilation that subsequently spreads systemically to recruit 
immune cells to the joints. 
We show that Stat5B is functionally significant in IgG XL-induced mediator release from mast 
cells (Figure III.1.B) but not macrophages (Figure III.4.C). Experiments using the Stat5 A/B 
inhibitor, Pimozide, showed that antagonizing both Stat5 A and B suppresses IgG-induced 
cytokine secretion from macrophages (Figure III.4.D). We further show that the difference in 
Stat5B KO mast cell and macrophage responses to IgG XL is not due to compensatory Stat5A 
upregulation or higher Stat5A expression among macrophages. In fact, in the absence of Stat5B, 
BMMC express approximately 5-fold more Stat5A than macrophages (Figure III.5). It could be 
that Stat5A and B are redundant only in the macrophage lineage, or that macrophages preferable 
utilize Stat5A for IgG-XL-induced mediator release. A final concern is that Pimozide, even at the  
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 low concentrations used, has off-target effects unrelated to Stat5. These questions will be 
investigated by transfecting siRNA specific for Stat5A and Stat5B in macrophages. 
Literature provides ample evidence supporting both views. Despite a high degree of 
structural homology among these paralogs, gene disruption studies in mice show phenotypic 
differences. For example, Stat5A KO mice possess poor mammary function, decreased 
hematopoietic stem cell proliferation, and reduced antibody class switching, while mice lacking 
Stat5B exhibit dwarfism and lymphopenia. On the other hand, the most dramatic phenotypes, 
like infertility, anemia, and perinatal lethality are evident only in mice lacking both paralogs. 
Genome-wide DNA binding profiles also support redundancy as well as specificity (50) (142).  
Previous studies from our lab have shown that although Fyn deficiency reduces cytokine 
release from mast cells and macrophages in vitro, and abrogates the release of histamine in vivo, 
it has no effect on the severity of IgG-induced PSA (55). On similar lines, we found that Fyn 
deficiency does not decrease the severity of K/BxN STA (Figure III. 8B, C), but the arthritic 
flare is milder in absence of Fyn (Figure III.8.A). These data suggest that in the absence of Fyn, 
mast cell, but not macrophage, responses are abrogated in vivo.  
Deficiency of Lyn has been linked to IgG-mediated autoimmunity in mice and humans 
but is mostly studied in the context of Lyn-regulated pathways in B cells (61-64). We know that 
Lyn kinase is a negative regulator of signaling downstream of Fcε and Fcγ receptors and is 
necessary to reduce pro-inflammatory signaling in mast cells. Its role downstream of Fcγ 
receptor crosslinking is conserved among macrophages and its deficiency exacerbates IgE- and 
IgG- mediated anaphylaxis (54, 55). Hence, we were curious to know the effects of Lyn 
deficiency on the severity of K/BxN STA. We have used Lyn KO mice that were on 129/Sv 
background. We found that Lyn KO mice developed significantly more severe arthritis than wild 
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type mice (Figure III.9. A, B), indicating that absence of this negative regulator of IgG signaling 
exacerbates IgG-induced inflammation in vivo.  
Our results contradict with a recent study (65) showing that Lyn KO mice had normal 
K/BxN-induced arthritis. The Lyn KO mice used in this study were on a C57BL/6 background. 
As previously noted by the Rivera laboratory, the mast cell Lyn KO phenotype varies among 
these two strains, partly because 129/Sv mast cells have higher Fyn kinase expression (66). We 
have since found that 129/Sv BMMC express 2.5-fold more Fyn, and 3-fold more Stat5 A/B than 
C57BL/6 BMMC (56). It is logical that the effects of losing a negative regulator could vary with 
the amount of positive regulator expression. As Lyn has a critical role in initiating signaling 
downstream IgE and IgG receptors and thus is a duel regulator, its negative regulatory role may 
be more prominent on 129/Sv background, where Fyn expression is more abundant. This could 
explain the discrepancies between the results.   
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Chapter III. Part 5. Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.1: IgG XL induces Fyn-dependent Stat5 activation that is required for cytokine 
secretion but not degranulation. (A) BMMC from WT and Fyn KO mice were activated by IgG 
XL for 5 minutes followed by fixation. Cells were stained with anti-phospho-tyrosine-Stat5 
antibody and analyzed by flow cytometry. (B) BMMC from WT and Stat5B KO mice were 
activated with IgG XL for 6 hours, and culture supernatants were analyzed by ELISA. (C) BMMC 
from WT and Stat5B KO mice were activated with IgG XL 10 minutes, then stained with anti-
CD107a antibody and analyzed by flow cytometry. Data are average of 3 (A), 4 (B), 2 (C) 
independent experiments performed in triplicate, using three separate BMMC populations. Two 
way ANOVA with Sidak’s multiple comparison test was used to calculate P values where * ≤ 0.05, 
** ≤ 0.01 and so on.  
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Figure III.2: Wild type and Stat5B KO BMMC exhibit similar developmental kinetics. BMMC were 
analyzed for percentage of mast cells on indicated days by flow cytometry. BMMC gated on CD45 were 
analyzed for FcεRI and c-Kit to quantify mast cells. A representative gating strategy (A) for cells analyzed 
on day 30 and quantification (B) of mast cells on indicated days are shown. The data represent one of 2 
independent experiments using three independent populations each and analyzed in triplicate.  
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Figure III.3: Stat5B deficiency does not offer protection during 2.4G2-induced passive 
systemic anaphylaxis. WT and Stat5B KO mice were injected i.v. with 500mg 2.4G2 
antibody. (A) Core body temperatures were noted at the indicated times post-injection using a 
rectal probe. (B) Mice were sacrificed 120 minutes post-injection, and cardiac punctures were 
performed. Plasma cytokines were analyzed by ELISA. Data are average of 2 independent 
experiments, in which n=4/treatment group 
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Figure III.4: Evidence for a role of Stat5A/B in IgG XL-induced cytokine production among 
macrophages. Bone marrow-derived macrophages were cultured from WT and Stat5B KO mice 
Materials and Methods. A representative sample depicting gating strategy (A) and quantification 
of mature macrophages after analysis by flow cytometry (B) are shown. (C) Supernatants 
collected from WT and Stat5B KO macrophages 6 hours after IgG XL were analyzed by ELISA. 
(D) WT Bone marrow derived macrophages were pret-reated for 2 hours with the indicated 
concentrations of Pimozide, followed by IgG XL. Supernatants collected 6 hours post-activation, 
were analyzed by ELISA. Data are average of 1 (A, B) and 3 (C) or are representative of 2 (D) 
independent experiments using three independent populations analyzed in triplicate. Two-way 
ANOVA with Sidak’s multiple comparison test (C) or one-way ANOVA with Dunnett’s multiple 
comparison test were used to calculate p values. 
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Figure III.5. Stat5A expression is not altered in Stat5B KO mast cells or 
macrophages. Lysates collected from 3 WT and 3 Stat5B KO mast cells (A) and 
macrophages (B) were assessed for Stat5A expression by Western blotting. Bar charts 
show average results of normalizing Stat5A signal intensity to GAPDH for each 
population.   
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Figure III.6. Stat5B deficiency does not alter the severity of K/BxN serum-induced arthritis. 25ml 
of K/BxN sera were injected i.p. on days 0 and 2 into WT and Stat5B KO mice. Clinical index (A), 
change in wrist thickness (B), and change in ankle thickness (C) were calculated on the indicated days 
post-injection. (D) Mice were sacrificed on day 8 post-injection and joint exudates were analyzed on 
flow cytometer. Total number of cells obtained from joint exudates after ACK lysis were counted. (E) 
Representative sample showing gating strategy for and quantification for neutrophils (F) detected in 
joint exudate. The data are representative of 2 independent experiments with 4-5 mice per treatment 
group.  
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Figure III.7. Stat5B deficiency significantly reduces the flare associated with K/BxN serum-induced 
arthritis. 50ml of K/BxN sera were injected i.p. into WT and Stat5B KO mice. (A) Mice were sacrificed 15-
minutes post injection and histamine level in joint exudates was analyzed by ELISA. Mice were injected as 
in (A) and Clinical index, change in wrist and ankle thickness (B) were noted 30 minutes post-injection. 
These mice were sacrificed 40 minutes (C) post-injection to analyze histamine concentration in joint 
exudates and plasma by ELISA. Data are representative of 2 independent experiments (B) and are SD of 4 
mice per group (A, C). 
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Figure III.8. Fyn kinase deficiency reduces K/BxN serum-induced flare but does not affect arthritis. 
100µl of K/BxN sera were injected i.p. into WT and Fyn KO mice on days 0 and 2. (A) Clinical index and 
the change in wrist and ankle thickness were calculated 30 minutes post-injection. (B) Clinical index and 
the change in wrist and ankle thickness were calculated on the indicated days post-injection. (C) Mice were 
sacrificed on day 9 post-injection and joint exudates were analyzed by flow cytometry as described in 
Figure III.6. Data are representative of 1 (A) and 2 (B, C) independent experiment with 4-6 mice per 
treatment group. 
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Figure III.9. Lyn kinase deficiency exacerbates the severity of K/BxN serum-induced arthritis.  
150µl of K/BxN sera were injected i.p. into WT and Lyn KO mice on days 0 and 2. (A) Clinical 
index and the change in wrist and ankle thickness were calculated on indicated days post-injection. 
(B) Mice were sacrificed on day 10 post-injection and joint exudates were analyzed on flow 
cytometer. Quantification for CD11-b+ cells (D) infiltrated in the joints was analyzed by flow 
cytometer. Data are average (A) and representative (B) of 2 independent experiments with 5 mice per 
treatment group. Area under the curve was calculated to determine p values in (A).  
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Chapter IV: Dexamethasone rapidly suppresses IL-33-mediated mast cell function 
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Chapter IV: Part 1: Abstract 
Mast cells are critical effectors of allergic disease. IL-33, a pro-inflammatory member of the IL-1 
cytokine family, is capable of activating mast cells and worsens the pathology of mast cell–
mediated diseases. As steroids are the mainstay of allergic disease treatment and are well known 
to suppress mast cell activation by other stimuli, we examined the effects of the synthetic 
glucocorticoid, dexamethasone, on IL-33-mediated mast cell function. We found that 
dexamethasone potently and rapidly suppressed cytokine production elicited by IL-33 from 
murine bone marrow–derived and peritoneal mast cells. It also antagonized IL-33-mediated 
enhancement of IgE-induced mast cell cytokine production. These effects were consistent in 
human mast cells. We additionally observed that IL-33 augmented migration of IgE-sensitized 
mast cells toward antigen. This enhancing effect was similarly reversed by dexamethasone. 
Although dexamethasone had no effect on IL-33-induced phosphorylation of MAP kinases or 
NFκB p65 subunit, dexamethasone antagonized AP-1- and NFκB-mediated transcriptional 
activity. Intraperitoneal administration of dexamethasone completely abrogated IL-33-mediated 
peritoneal neutrophil recruitment and prevented plasma IL-6 elevation. These data demonstrate 
that steroid therapy may be an effective means of antagonizing the effects of IL-33 on mast cells 
in vitro and in vivo, acting partly by suppressing IL-33-induced NFκB and AP-1 activity. 
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Chapter IV. Part 2. Introduction 
IV. 2.1. IL-33 
In 2005, efforts of Schimtz J et al. brought to light a new member of the IL-1 family, IL-
33 (IL-1F11) (67), which is now recognized to play a critical role in innate and adaptive 
immunity (68). The human gene for IL-33 is located on chromosome 9p24.1, while its mouse 
counterpart is on chromosome 19qC1. The cDNA for human and mouse IL-33 encodes 270 and 
266 amino acids, while full length proteins are 30 and 29.9 kDa, respectively. At the amino acid 
level, human and mouse IL-33 are 52-55% identical (67). Interestingly, in the mouse genome, 
two alternate promoters generate two distinct transcripts (IL33a and IL33b) which encode the 
same protein (69). 
Phylogenetic analysis indicated that IL-33 protein is evolutionarily conserved in 
mammals. Of all the IL-1 family members, IL-33 is most closely related to IL-18 (67). The 
carboxy-terminal region of IL-33 corresponds to an IL-1-like cytokine domain containing 12 β 
strands arranged in a β-trefoil fold, and has a three dimensional structure similar to other family 
members (70, 71). The amino-terminal domain is necessary and sufficient for nuclear 
localization and chromatin association. This is why IL-33 was also initially called nuclear factor 
from high endothelial venules (NF-HEV) (72, 73).   
The N-terminal chromatin binding motif is evolutionarily conserved as well, suggesting 
that nuclear localization and binding to chromatin must be critical for function and/or regulation 
of IL-33 (74). In support of this notion, studies so far have shown that nuclear IL-33 can function 
as a transcriptional repressor when overexpressed in transfected cells (75), and a knock-in mouse 
lacking N-terminal nuclear domain of IL-33 exhibits elevated levels of serum IL-33 and 
inflammation-induced lethality (76). However, we lack sufficient evidence to confidently say 
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that nuclear IL33 is a critical transcriptional regulator functioning in the pro-inflammatory 
activities for which IL-33 is known. 
Due to the N-terminal motif, IL-33 is predominantly expressed in the nucleus, expressed 
at high levels in endothelial, epithelial, and fibroblast-like cells in the steady state. Specifically, 
epithelial cells in barrier tissues close to the environment, fibroblastic reticular cells in lymphoid 
organs (77, 78), and glial cells in nervous tissue are major sources of IL-33. However, expression 
of IL-33 protein exhibits some species-specific differences. For example, unlike humans, IL-33 
is not constitutively expressed along the vascular tree in mice; instead it can be detected in some 
vascular beds (77). IL-33 expression, already abundant at steady state, further increases during 
inflammation as observed in the airway epithelium from patients with chronic pulmonary 
obstructive disorder (COPD), in skin keratinocytes and blood vessels from patients suffering 
from atopic dermatitis (79), in murine alveolar type II pneumocytes following nematode 
infection (80), in intestinal epithelia from patients with graft versus host disease (GVHD)(81), 
and among fibroblast-like cells and myofibroblasts in diseases associated with tissue fibrosis (82, 
83). 
  IL-33 lacks a signal sequence and hence is not secreted from cells like conventional 
cytokines (84). Instead, it is released after cell injury, alerting the immune system to tissue 
damage following trauma or infection. For example, intranasal administration of allergens results 
in an immediate increase in IL-33 in bronchoalveolar lavage and nasal lavage (85). Similarly, 
central nervous system injury is followed by rapid release of IL-33 in cerebrospinal fluid from 
damaged oligodendrocytes, promoting immune cell recruitment and tissue repair (86). Therefore 
IL-33 is often referred to as an alarmin. Though further studies are needed to clarify the possible 
mechanisms of IL-33 release, constitutive expression in structural human tissue, release into 
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extracellular space following a mechanical injury or necrotic cell death, and biological activity of 
the full length protein (78) underline the role of IL-33 as an endogenous danger signal.  
Unlike its family members IL-1β and IL-18, it is not clear whether CD45+ hematopoietic 
cells constitute an important source of IL-33 (67). During inflammation, mRNA levels for IL-33 
are indeed induced in hematopoietic cells but are still lower than those found in structural tissues, 
making epithelial, endothelial, fibroblast-like and bone marrow stromal cells the chief sources of 
IL-33 during inflammation (69).  
Initially it was thought that full length IL-33 is inactive and is activated through cleavage 
by caspase-1 (67), similar to the classical family members, IL-1β and IL-18. Later studies 
showed that in case of IL-33, the caspase-cleavage site is different than the proposed one and 
falls within the IL-1-like domain making the resulting products biologically inactive (87, 88). 
Although full length IL-33 (30 kDa) is functional, proteases from mast cells and 
neutrophils can generate a shorter (18-21 kDa) form that encompasses the IL-1-like cytokine 
domain and is 10- to 30-fold more potent than the full length form. Importantly, a shorter, more 
potent form of endogenous IL-33 has also been found in vivo, during inflammation. These 
studies suggest that while mast cell proteases generate mature IL-33 during allergic inflammation, 
neutrophil protease do the same during infection (89, 90). 
 The discovery of IL-33 was preceded by the description of its primary receptor, ST2 
(suppression of tumorigenicity), also known as T1, IL-1RL-1 and IL-33R.  The surface charge 
complementarity ensures specific binding of IL-33 cytokine to ST2. The IL-33-ST2 complex 
provides a platform for binding of another receptor chain called IL-1RAcP (IL-1RAP). The 
ternary complex thus formed, juxtapositions cytoplasmic Toll/IL-1R (TIR) domains of ST2 and 
IL-1RAcP, resulting in activation of intracellular signaling (67, 70, 71). The ST2 and IL-1RAcP 
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heterodimer leads to recruitment of myeloid differentiation and primary response protein 88 
(MYD88), IL-1R associated kinase-1 (IRAK-1), IRAK-4, and tumor necrosis factor receptor 
associated factor 6 (TRAF6), ultimately resulting in activation of mitogen-activated protein 
kinases (MAPKs) and NFĸB. A wide variety of cells in the body express IL-33 receptor, 
including Th2 cells, ILC2, dendritic cells, basophils, eosinophils, and mast cells (67). 
 
IV. 2.2. Mast cells and IL-33 
Soon after the discovery of IL-33, studies uncovered its role in mast cell activation. 
While IL-33 cannot induce degranulation or eicosanoid production, it stimulates robust 
cytokine/chemokine release from mast cells independent of FcεR activation (91). IL-33 also 
amplifies cytokine production downstream of Ag-IgE crosslinking (92). 
Single nucleotide polymorphisms in the IL-33 gene are associated with asthma 
susceptibility. Elevated levels of IL-33 mRNA in the airway smooth muscles and lung 
epithelium and elevated soluble ST2 levels in the serum are typical features of asthmatic patients 
as well as murine models airway inflammation. Administration of anti-IL-33 antibody or soluble 
ST2-Fc fusion protein significantly inhibits Th2-associated responses, serum IgE levels, and 
bronchoalveolar eosinophilia, ultimately reducing airway inflammation (93).   
A recent study by Adner and colleagues showed that IL-33 pre-treatment enhanced 
allergen-induced contractions of airway smooth muscles in vivo and ex vivo. These effects were 
absent in animals lacking mast cells or those lacking ST2. Interestingly, in wild type mice, the 
serotonin receptor antagonist, ketanserin, blocked the exaggeration of airway obstruction. 
Related to this, in cultured mast cells IL-33 increased synthesis, storage and secretion of 
serotonin following IgE receptor crosslinking. Collectively, these data suggested that IL-33 
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exaggerates allergic bronchoconstriction through elevated release of serotonin from mast cells 
(94). A related study by Kaur et al showed that IL-33 activates mast cells located in airway 
smooth muscle bundle to produce IL-13, which contributes to airway hyper-responsiveness (95). 
These studies suggest that IL-33-mediated mast cell activation presents an important target to 
modulate mast cell-airway smooth muscle crosstalk.  
 
IL-33 is highly expressed by synovial fibroblasts in patients with rheumatoid arthritis.  
Murine models of collagen-induced or K/BxN sera-induced arthritis have uncovered the role of 
IL-33 in inflammatory joint diseases. ST2-/- mice develop a milder disease, and administration of 
anti-ST2 antibodies to wild type mice at the onset of arthritis reduces disease severity. 
Conversely, administration of exogenous IL-33 to wild type but not ST2-/- mice worsens the 
disease. Interestingly, ST2-/- animals demonstrated impaired mast cell-dependent immune 
complex-induced vascular permeability (flare) during K/BxN arthritis. Wild type, but not ST2-/- , 
mast cells restored the ability of ST2-/- mice to mount the IL-33-induced flare, highlighting the 
mast cell contribution towards pro-inflammatory effects of IL-33 (96, 97). At a cellular level, IL-
33 not only induces the release of inflammatory mediators directly but also primes mast cells for 
IgG-immune complex-mediated stimulation through FcγRIII (98). IL-33 produced by synovial 
fibroblasts enhances mast cell mRNA and protein accumulation of mMCP-6, an ortholog of 
human tryptase-β, promoting the pro-inflammatory role of mast cells in inflammatory arthritis 
(99).   
 Recent studies have established that the IL-33-ST2 pathway leads to upregulation of the 
anti-apoptotic molecule BCL-XL and hence contributes towards longer persistence of mast cells 
in inflamed tissues. Thus targeting this pathway might attenuate mast cell accumulation (100). 
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Neutralizing IL-33 reduces late-phase responses during antigen-induced passive cutaneous 
anaphylaxis (101). These studies collectively support the rationale for targeting IL-33 in mast 
cell-mediated diseases. 
   
IV. 2. 3. Dexamethasone 
Dexamethasone, first synthesized in 1957, is the most potent member of the anti-inflammatory 
steroid family. It has been widely used for the treatment of asthma, rheumatoid arthritis, 
bronchial asthma, allergy, lupus, and ulcerative colitis. It is 25 times more potent than cortisol, 
an endogenous glucocorticoid (102-104). Dexamethasone effectively suppresses IgE-mediated 
mast cell degranulation, lipid mediator release and cytokine production in vitro, and suppresses 
passive cutaneous anaphylaxis and wheal and flare reactions in vivo (104-108). A relatively 
recent study showed that dexamethasone suppressed IL-33-mediated acute lung inflammation 
(109). This prompted us to characterize the effects of dexamethasone on IL-33-induced mast cell 
function in vitro and in vivo. 
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Chapter IV. Part 3. Results 
 Previous studies have highlighted the importance of dexamethasone (Dex) pre-treatment 
length for obtaining maximum suppression of IgE-induced mast cell mediator release (104, 105). 
Hence, to characterize the effects of Dex on IL-33-induced mast cell activation we first 
investigated effects of pre-treatment timing. BMMC obtained from C57BL/6J mice were treated 
with Dex up to 24 hours prior to IL-33-stimulation. While Dex pre-treatment reduced IL-33-
induced TNF and IL-6 secretion at all times, maximum suppression was obtained with 0-8 hour 
pre-treatment (Figure IV.1.A). To investigate whether Dex can exhibit its suppressive effects 
after activation has begun, BMMC were given Dex at 2 or 4 hours after stimulation with IL-33. 
Drug treated cells exhibited reduced secretion of IL-6 and TNF when Dex was added 2 hours 
after stimulation, however the suppression did not reach significance (Figure IV.1.A). 
Since these data indicated rapid and relatively short-acting suppressive effects, Dex was 
added simultaneously with IL-33 in further experiments. Dose-responses analyses for 
suppression of IL-6, TNF and IL-13 revealed an IC50 of approximately 5nM, while for MCP-1 
this was 10-fold higher, at 50 nM (Figure IV.1.B). BMMC are primary cells but their in vitro 
differentiation might alter drug responsiveness. Therefore, we utilized murine peritoneal mast 
cells expanded ex vivo, which revealed suppressive effects similar to BMMC (Figure IV. 1.C) 
Previous studies in our lab showed suppression of IgE-induced responses in C57BL/6 
mast cells treated with TGFβ1 or fluvastatin, while mast cells from 129/sv mice were resistant to 
these effects, indicating differential sensitivity likely related to genetic background (56, 110). In 
contrast, 129/sv BMMC were equally responsive to Dex as there was no significant difference in 
the IC50 values for suppressing IL-33-mediated cytokine secretion, compared to those of 
C57BL/6 BMMC (Data not shown).  
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Decreased cytokine release can be due to reduced production or secretion. To 
differentiate this, we performed in-cell staining for TNF on IL-33-stimulated BMMC treated 
with vehicle or Dex (Figure IV. 2.A). Dex significantly reduced the fraction of TNF-producing 
cells, indicating that Dex is acting at the level of cytokine protein induction rather than its 
secretion. We further analyzed mRNA synthesis for cytokines. RT-qPCR data showed that IL-33 
stimulation induces IL-6 and TNF mRNA 4-8 fold compared to control cells, an effect 
significantly suppressed by Dex. We also noted a reduction in basal TNF mRNA levels among 
Dex-treated BMMC (Figure IV. 2.B).    
To confirm that the effects of Dex are being mediated via the glucocorticoid receptor 
(GR), BMMC were pre-treated with GR antagonist RU-486 before addition of dexamethasone. 
RU-486 completely abolished Dex suppressive effects, indicating the need of GR function 
(Figure IV.3). Collectively, these data indicate that dexamethasone is a potent and rapid 
suppressor of IL-33-induced mast cell mediator release, acting at least partly to suppress IL-33-
induced transcription.  
  One of the mechanisms behind Dex-mediated cytokine suppression could be reduced 
surface expression of the IL-33 receptor ST2, an essential component for IL-33-induced mast 
cell activation (93). To test this, BMMC were treated with Dex for up to 24 hours and analyzed 
for ST2 surface expression by flow cytometry. This revealed a modest decrease in the levels of 
surface ST2 starting at 6 hours after Dex addition (Figure IV.4.A). Since ST2 receptor 
downregulation required a longer treatment time than Dex effects on cytokine secretion, this 
cannot be the main explanation for inhibition caused by simultaneous addition of the drug with 
IL-33. However, this downregulation might contribute to effects of Dex at later time points. We 
found that at the 24 hour time point, the reduction in ST2 expression is dose-dependent, with 
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maximal suppression occurring at Dex concentrations greater than 10nM (Figure IV.4.B). It was 
interesting to note that Dex had modest impact on the percentage of ST2+ cells, which remained 
above 80% after treatment. Rather, the staining intensity for ST2 dropped by nearly 60% among 
the drug-treated group, indicating that fewer receptors are expressed per cell after exposure to the 
drug (Figure IV.4.B).  
We next explored the relationship between ST2 receptor expression and cytokine protein 
expression at the 24-hour treatment time point. The staining intensities of IL-6 or TNF were 
plotted as a function of ST2 receptor expression among IL-33 activated cells treated with Dex or 
vehicle (Figure IV.4.C). To generate a plot of average ST2 expression versus average cytokine 
staining intensity, cells were gated by groups based on ST2 receptor expression. These plots 
showed a non-linear relationship between ST2 receptor levels and cytokine production, 
indicating a low threshold for ST2-mediated cytokine production that changes little when ST2 
expression is increased or decreased. Dex-treated cells exhibited lower staining intensity for 
cytokines compared to that of the vehicle-treated group, irrespective ST2 staining. These data, 
coupled with the delay in ST2 downregulation, indicate that inhibiting ST2 expression is not 
critical for Dex-mediated antagonism of cytokine production.  
If ST2 downregulation is not the mechanism behind cytokine suppression, Dex likely acts 
by antagonizing IL-33 signaling. Recruitment of the adaptor protein MyD88, leading to IRAK 
and TRAF6 activation, are the prototypical events downstream IL-1 family receptor signaling, 
including ST2. These events result in phosphorylation of MAP kinases and activation of the 
transcription factors AP-1 and NFκB (67, 91, 111). Hence, we assessed Dex effects on ERK, 
JNK, p38, and NFκB subunit-p65 phosphorylation after IL-33 stimulation. Dex had no effect on 
the timing or magnitude of phosphorylation (Figure IV.5). To determine if Dex treatment affects 
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the activity of downstream transcription factors, we employed luciferase reporter plasmids. Dex 
significantly suppressed IL-33-induced NFκB transcriptional activity, and completely abrogated 
AP-1 function (Figure IV.6). These results indicated that Dex largely alters the late stages of IL-
33 signaling, while early phosphorylation signals were unaffected.  To verify that Dex mediated 
suppression in cytokine production is not a result of cell death, we verified cell viability at 
different time points after Dex addition and found observed no significant cells death with 
treatments shorter than 48 hours (Data not shown).    
  A recent study by the Beaven group demonstrated that IL-33 enhances FcεRI-induced 
mast cell function, an effect that might be critical in the context of allergic inflammation (92). 
Therefore, we assessed the capacity of Dex to suppress this synergy. Using relatively high doses 
of antigen and IL-33, we too observed enhanced cytokine secretion (Figure IV.7.A). Dex 
inhibited cytokine and chemokine secretion by same fold under single or co-stimulation 
conditions, showing that it can suppress the augmenting properties of IL-33.  
Mast cells migrate towards many stimuli, including antigen. We determined whether IL-
33 exerts enhancing effects on mast cell migration towards antigen and if Dex inhibits this. 
Using transwell chambers, we observed that IL-33 alone did not induce BMMC migration, but 
its presence in the bottom chamber enhanced Ag-mediated migration of IgE-sensitized mast cells. 
While Dex did not suppress migration towards antigen, it abolished the IL-33-induced 
enhancement, reducing net migration to the level of antigen alone (Figure IV.7.B). 
Enoksson et al. showed that an intraperitoneal (i.p.) injection of IL-33 yields neutrophil 
recruitment to the mouse peritoneum. This effect was dependent on IL-33-mediated mast cell 
activation via receptor ST2 (112). To investigate if dexamethasone can alter this, we 
administered dexamethasone i.p., followed by either PBS or IL-33. Cells isolated from peritoneal 
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lavage were analyzed by flow cytometry. As expected, IL-33-administered mice had 
significantly more neutrophils in their peritoneum compared to PBS-injected mice, which had 
negligible neutrophils in the peritoneum (Figure IV.3.8.A). Dex injection completely abrogated 
IL-33-induced neutrophil recruitment and also reduced plasma IL-6 levels to baseline, nullifying 
the effects of IL-33 (Figure IV.8.B). These data agree with our in vitro findings, demonstrating 
that Dex effectively antagonizes IL-33-mediated inflammation in vivo.  
  It is important to verify whether Dex-mediated suppression of IL-33 function varies 
between species. Human skin mast cells isolated from 4 healthy donors were activated with IL-
33 and/or IgE+antigen. IL-33 stimulation weakly induced TNF and MCP-1 production, which 
was suppressed by Dex in 3 out of 4 donors. While Dex generally suppressed IgE-induced 
cytokine production as expected, there was donor-to-donor variability. Co-stimulation with IL-33 
and IgE/antigen resulted in the greatest cytokine production, which was consistently suppressed 
by dexamethasone. These data suggest that IL-33-mediated activation of human and mouse mast 
cells is similarly sensitive to dexamethasone. 
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Chapter IV. Part 4: Discussion 
The past decade has shed light upon pro-inflammatory effects of IL-33 and has also 
highlighted the role of IL-33-mediated mast cell activation in exacerbating allergic diseases. 
Steroids have been the mainstay of allergic disease treatment, but steroid effects on IL-33-
stimulated mast cell function have not been examined. Hence, we characterized the effect of 
dexamethasone on IL-33-mast cell activation in vitro and in vivo. 
Our time course experiments showed significant suppression of cytokine secretion when 
Dex was added up to 8 hours prior to or simultaneously with IL-33 stimulation (Figure IV.1.A). 
The fact that the suppression achieved with simultaneous addition of Dex and IL-33 was greater 
than that obtained by 24 hour pre-treatment, highlighted rapid but transient actions of Dex. As 
longer pre-treatment time also includes variables like autocrine and paracrine receptor signaling, 
we focused our investigation on simultaneous addition of Dex and IL-33.  
 The ubiquitously expressed GR is present in the cytoplasm under basal conditions. 
Passive diffusion of Dex leads to translocation of the ligand-bound receptor into the nucleus. 
This activated GR complex can directly bind to glucocorticoid response elements (GRE) to 
activate the transcription of target genes (trans-activation) and also can interact with other 
transcription factors to block transcription (trans-repression) (113).  
 Dex can additionally affect receptor-proximal signaling events by inactivating MAPKs. 
As this depends on de novo transcription of MAPK phosphatase-1, it requires several hours of 
Dex treatment to manifest (114-118). When added simultaneously with the stimulatory signal, 
Dex mainly blocked AP-1 and NFĸB transcriptional activity (Figure IV.6) without altering 
phosphorylation events (Figure IV.5). Studies suggest that direct physical interaction between 
ligand-bound GR and the transcription factor complexes is the reason behind this transcriptional 
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inhibition (113, 119-121). Our luciferase reporter assay results were reinforced by the decline in 
TNF and IL-6 mRNA expression (Figure IV.2.B). Collectively, these data indicated that 
simultaneous addition of Dex with IL-33 suppresses mediator release mainly through inhibiting 
activity of pro-inflammatory transcription factors. 
 Consistent with previous studies (91, 92), we also noted that IL-33 enhances IgE-
mediated cytokine production in murine and human mast cells. Dex suppressed this synergy, 
reducing the amount of mediators released to the levels comparable to individual stimuli. These 
observations are critical, as they demonstrate the ability of Dex to nullify the enhancing effects 
of IL-33. But they also indicate limitations of Dex therapy, which was unable to reduce cytokine 
production to background levels. 
 Chemokines and antigens have the potential to act as chemotactic factors for mast cells, 
leading to their accumulation in asthma, atopic dermatitis, arthritis, psoriasis (122, 123). These 
inflammatory foci generally exhibit high expression of the alarmin, IL-33 creating a niche rich in 
both antigen and IL-33. Hence, we decided to investigate how IL-33 affects mast cell migration 
towards antigen. We demonstrated for the first time that IL-33 enhances migration of IgE-
sensitized mast cells towards antigen (Figure IV.7.B), similar to its effects on mast cell cytokine 
secretion. In our system, Dex did not suppress migration towards antigen alone, but did reduce 
IL-33-induced enhancement. Mast cell migration towards antigen is a complex process involving 
activation of signaling proteins including p38 MAPK, ERK, Syk, the GTPase Rho, S1P and 
Orail-1-induced calcium influx (122-125). Dex effects on these individual pathways could reveal 
its inability to suppress migration towards antigen, while suppressing the enhancing effects of 
IL-33. However, these data demonstrate that Dex has the capacity to reduce mast cell 
accumulation in pathology associated with IL-33 function. 
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 Studies have pointed at the role of mast cells in neutrophil recruitment in certain allergic 
and autoimmune diseases, including bullous pemphigoid, experimental autoimmune 
encephalomyelitis, and urticaria (126-128). A recent study demonstrated that following IL-33 
injections, local mast cell activation and neutrophil recruitment contributes to the development of 
psoriatic skin lesions (129). This discovery showed IL-33 upstream of mast cell-mediated 
neutrophil infiltration pathway. A similar study re-emphasized this by showing that mast cells 
are critical for neutrophil recruitment after IL-33-induced peritoneal inflammation (112). We 
utilized this model of peritonitis and found that Dex blocks IL-33-induced neutrophil recruitment 
to the peritoneum (Figure IV.8.A) and also reduces systemic IL-6 levels (Figure IV.8.A). 
Although previous studies have indicated that mast cells play a critical role in neutrophil 
recruitment, it is important to realize that Dex could be affecting many cell types in our assay, as 
IL-33 acts on multiple immune lineages. However, our data do demonstrate that Dex acts as an 
antagonist for IL-33-induced inflammation in vivo.  
As mast cell phenotype varies with anatomical location (123), we felt the need to verify 
suppressive effects of Dex on mast cells beyond BMMC. We observed that Dex had similar 
effects on mouse peritoneal mast cells (Figure IV.3.1.B), which differentiate in vivo before 
expanding in vitro. Dex effects were also consistent between different strains (Figure IV.1.D). 
Since IL-33 alone is a poor activator of human mast cells, we investigated IL-33-induced 
enhancement of FcεRI-mediated mast cell responses. Dex suppressed IL-33 effects on mast cells 
from 4 donors (Figure IV.3.9), albeit with donor to donor variability in Dex responses. We 
postulate this is likely due to genetic differences, since skin mast cells are cultured for at least 8 
weeks prior to use, limiting environmental effects. Interestingly, we did not observe variable Dex 
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effects between C57BL/6 and 129/Sv BMMC, two strains with many polymorphisms that have 
shown variable responses in our previous assays (56, 110). 
Collectively, our data demonstrate that dexamethasone, a member of the clinically 
important steroid family, potently suppresses IL-33-mediated mast cell functions, including 
cytokine-chemokine production, migration, and neutrophil infiltration.  
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Chapter IV. Part 5: Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IV.1. Dexamethasone suppresses IL-33-mediated cytokine secretion in mouse BMMC 
and peritoneal mast cells.  BMMC were treated with 2µM (A) or indicated concentrations (B) of 
Dex at indicated times in (A) or simultaneously with IL-33 (50 ng/ml) in (B). Cells were stimulated 
with IL-33 for 6 hours and supernatants were analyzed by ELISA. The dotted line indicates 
background cytokine production without activation. (C) Supernatants obtained from murine 
peritoneal mast cells activated with IL-33 (50ng/ml) and simultaneously treated with vehicle or Dex 
(1 µM) for 6 hours were analyzed by ELISA. Data shown are representative of 3 independent 
experiments performed with 3 independent cultures each and analyzed in triplicate. Unpaired 
Student’s t-tests were performed to compare vehicle-treated and Dex-treated cells at each time point 
in (A). Dunnett’s multiple comparison test was performed to compare each group treated with a 
particular dose of Dex or Vehicle control group in (B). Tukey’s multiple comparison test was used to 
calculate p values in (C). 
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Figure IV.2. Dexamethasone-mediated 
suppression of IL-33-induced cytokines is 
evident at protein and mRNA levels. (A) 
BMMC were treated with 1 µM Dex and 
simultaneously activated with IL-33 (50 
ng/ml) for 6 hours. TNF production was 
analyzed by intracellular staining and flow 
cytometry. Dot plots are representative of 3 
BMMC populations. Numbers indicate 
percentage of cells positive for TNF. Bar 
chart shows quantification of vehicle- or 
Dex-treated cells (lower panel). (B) BMMC 
were treated and activated as described in 
(A) for 2 hours. Cytokine mRNAs were 
measured by RT-qPCR. Fold induction was 
calculated by normalizing treatment groups 
to the vehicle treated, un-activated group. 
Data shown are representative of 3 (A) and 
an average of 2 (B) independent experiments 
performed with 3 independent BMMC 
populations each and analyzed in triplicate. 
Tukey’s multiple comparison test was used 
to calculate p values in (B). 
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Figure IV. 3 Dexamethasone effects are prevented by glucocorticoid receptor antagonism. BMMC 
were treated with RU-486 (0.5µM) for 1 hour before adding IL-33 (50ng/ml) +/- Dex (0.1 µM). 
Supernatants collected 6 hours after activation were analyzed by ELISA. Data shown are representative 
of 3 independent experiments performed with 3 independent BMMC populations each and analyzed in 
triplicate. Tukey’s multiple comparison test was used to calculate p values. 
 
 
 
  
  
 
64 
 
 
 
 
 
 
 
Figure IV. 4. Dexamethasone decreases ST2 
receptor expression. (A) Analysis of ST2 surface 
expression on BMMC treated with 1 µM Dex for 
the indicated times. ST2 was detected by flow 
cytometry. (B) Change in ST2 surface expression 
after 24-hour exposure to the indicated dose of Dex, 
as measured by flow cytometry. gMFI indicates 
geometric mean fluorescence intensity. (C) Staining 
intensities for cytokines versus ST2 receptor 
expression on BMMC pre-treated with Dex (1 µM) 
for 24 hours and activated with IL-33 (50ng/ml). 
Data shown are representative of 3 independent 
experiments performed with 3 independent BMMC 
populations each and analyzed in triplicate. 
Dunnett’s multiple comparison test was performed 
to compare drug and vehicle treated groups in (B). 
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Figure IV. 5. Dexamethasone does not alter rapid IL-33 signaling events. BMMC were left un-
activated (0) or activated with IL-33 (100 ng/ml) plus simultaneous addition of vehicle or Dex (2 µM). 
Lysates collected at 5 and 15 minutes after activation were used for Western blotting. Representative blots 
are shown. Normalized signals for individual time points are shown in bar charts, plotted as fold of 
untreated cells. Data shown representative of 2 independent experiments, each using 3 independent 
BMMC populations.   
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Figure IV. 6. Dexamethasone suppresses NFκB and AP-1 transcriptional activity. 
(A-B) BMMC transfected as described in Materials and Methods were activated with 
IL-33 (50 ng/ml) and simultaneously treated with vehicle or Dex (2 µM) for 2 hours. 
Ratios of signal for Firefly luciferase to that of Renilla luciferase for individual 
samples were normalized to that of vehicle-treated cells. Data are average of 2 
independent experiments performed with 3 sets of transfectants and analyzed in 
triplicate. Tukey’s multiple comparison test was used to determine p values. 
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Figure IV. 7. Dexamethasone suppresses IL-33-induced enhancement of IgE-mediated responses. (A) 
IgE-sensitized BMMC were either activated with IL-33 (50 ng/ml) alone, 50 ng/ml of antigen alone (XL), 
or both together, and simultaneously treated with vehicle or Dex (1 µM). Supernatants collected 6 hours 
after activation were analyzed by ELISA. Data are representative of 3 independent experiments done in 
triplicate. (B) IgE-sensitized BMMC were assessed for migration in response to Ag (50ng/ml; XL) or IL-33 
(50ng/ml) as described in Materials and Methods. Fold migration was normalized to migration towards 
media alone. Tukey’s multiple comparisons test was performed to calculate p values. Data are 
representative of 3 independent experiments done in triplicate.  
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Figure IV. 8. Dexamethasone blocks IL-33-induced inflammation in vivo. C57BL/6 mice injected with 
vehicle or Dex were subsequently injected with PBS or IL-33 as described in Materials and Methods 
section. Four hours later, neutrophil recruitment was determined by flow cytometry analysis of peritoneal 
lavage cells (A) and plasma IL-6 levels were measured by ELISA (B). Data are representative of two 
independent experiments where n=5 per treatment group. Tukey’s multiple comparisons test was 
performed to calculate p values.  
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Figure IV. 9. Dexamethasone suppresses IL-33-induced cytokine production from human 
skin mast cells. IgE-sensitized human skin mast cells from 4 healthy donors were activated with 
IL-33 (100 ng/ml), antigen (50 ng/ml), or both together, and simultaneously treated with vehicle 
or Dex (1 µM). Supernatants collected 16 hours after activation were analyzed by ELISA. Data 
are ±SD of 6 replicates per sample. P values indicate differences between relevant pairs of 
samples +/- dexamethasone. 
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